Your session is about to expire
← Back to Search
MAS825 for Autoinflammatory Diseases (MASter-1 Trial)
MASter-1 Trial Summary
This trial is testing a new drug to see if it is effective and safe for patients with NLRC4-GOF.
MASter-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMASter-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 140 Patients • NCT04382651MASter-1 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I weigh at least 3 kg.I agree to use effective birth control during MAS825 therapy.I have NLRC4-GOF, XIAP deficiency, or CDC42 mutations and am in a Novartis MAP for MAS825.I have a genetic condition related to NLRC4, XIAP, or CDC42 and show signs of inflammation.I tested positive for tuberculosis recently.You have medical conditions or problems that the doctor believes would make it too risky for you to receive MAS825 therapy.I haven't taken certain immune system affecting drugs recently before starting MAS825, except for some allowed ones.I have Takenouchi-Kosaki syndrome with CDC42 mutation.I weigh more than 160 kg.I have not received any live vaccines in the month before starting MAS825, and I won't during or for 3 months after the trial.I don't have any serious ongoing infections, except for chronic EBV.
- Group 1: MAS825
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has MAS825 been granted regulatory clearance by the Food and Drug Administration?
"MAS825 has been granted a safety rating of 2, given that it is in the midst of Phase 2 trials. While there is evidence attesting to its security at this stage, efficacy remains unconfirmed."
What other research projects have been completed that involve MAS825?
"MAS825 was initially tested at Novartis Investigative Site in 2019, with over 18325 trials having been concluded. At the present moment, two studies are actively seeking patients and both of those can be found in Montreal, Quebec."
In what geographical areas is this scientific experiment taking place?
"As of now, this clinical trial is sourcing participants from a total of 6 sites. These are situated in Montreal, Cincinnati and Seattle alongside 3 other spots. To minimize the amount of travel needed to take part, it's recommended that you pick the closest clinic for enrollment."
How many participants are currently being observed in this clinical investigation?
"The pharmaceutical company Novartis Pharmaceuticals is sponsoring the trial and will be administering it from Montreal, Quebec and Cincinnati, Ohio. To conduct this research 8 participants fulfilling specific criteria must be identified."
Is this research endeavor recruiting participants yet?
"Clinicaltrials.gov reports that this medicinal experiment is currently enrolling patients with the first post on December 18th 2020, and last update occurring October 31st 2022."
What makes this experimental trial distinct from others?
"MAS825 has been investigated since 2019, when Novartis Pharmaceuticals sponsored its first clinical trial involving 200 participants. After the successful completion of Phase 1, MAS825 was granted approval for its second testing phase. Currently there are active research studies in 23 cities and 15 countries dedicated to examining this medication's efficacy."
Share this study with friends
Copy Link
Messenger